On September 1, Hengrui Pharmaceutical's Class 1 innovative biopharmaceutical, Suldi Insulin Injection, was first launched at Ali Health. This is the first self-developed long-term insulin analogue in China for the treatment of type 2 diabetes in adults. The drug is only one month from approval to launch. The industry believes that this reflects the further shortening of the link between approval and accessibility of innovative drugs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.